BioStock: PHI’s CEO comments on the approved US listing

August 21, 2024
Language flag

Phase Holographic Imaging has been approved for a dual US listing in addition to its primary listing on the Swedish Spotlight market. What does this mean for the company’s shareholders, and how might it impact the company’s long-term valuation? BioStock reached out to PHI’s CEO Patrik Eschricht to discuss this and the upcoming redemption of the TO4 warrants that could potentially raise SEK 20.8 million in October.

Read the full interview with Patrik Eschricht on biostock.se.

The dual listing on the OTCQB market represents a significant step in
making PHI’s shares more accessible to US investors. This listing
increases our visibility in the US, aligning with our strategic focus on
expanding into the regenerative medicine market.

Further reading

Biostock-PHI-US-listing-interview

BioStock: PHI aims for US listing

BioStock has talked to PHI’s CEO, Patrik Eschricht, to learn more about what the dual listing on the US OTCQB market means for the company and its plans for the future.
biostock-phi-grows-its-network-of-collaborations-wheels-in-motion

BioStock: PHI grows its network of collaborations

BioStock caught up with PHI’s CEO Patrik Eschricht to ask about his outlook for the growing number of academic collaborations and sales partnerships.
phi-right-moment-to-capitalize-on-regenerative-medicine-momentum

BioStock: PHI “It’s the right moment to capitalize on regenerative medicine momentum.”

BioStock contacted CEO Patrik Eschricht for an update on the company’s progress and how PHI will capitalize on the current momentum.
PHI-biostock-shift-to-regenerative-medicine-increases-growth-prospects-for-phi

BioStock: Shift to regenerative medicine increases growth prospects for PHI

BioStock talked to our CEO, Patrik Eschricht, for an operational overview and to learn about the current behind-the-scenes developments, as PHI has a growth trajectory that is on a notable upward trend, marked by its highest-ever sales performances in the last quarter.
1234…8

Latest News

phi-right-moment-to-capitalize-on-regenerative-medicine-momentum

BioStock: PHI’s new CEO: “I am excited to lead us forward with new energy”

Anders Månsson was recently appointed CEO of Phase Holographic Imaging. With extensive leadership experience in the international life sciences sector, he aims to expand PHI’s global reach and position the company as a leader in non-invasive cell quality control technologies. BioStock spoke with him about his vision for the future.

Bulletin from the annual general meeting of Phase Holographic Imaging PHI AB (publ)

Phase Holographic Imaging PHI AB (publ) held its annual general meeting on 31 October 2024. The following resolutions were made.

PHI secures a loan from Altium SA

Phase Holographic Imaging PHI AB (“PHI”) announces that the Company has been provided a loan of SEK 7 million from the main shareholder Altium SA. PHI and Altium SA are also in dialogues regarding long-term financing of PHI.
See All News